Latest Breaking News On - Amy figueroa - Page 1 : vimarsana.com

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 15, 2024 -- Caribou Biosciences, Inc. , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the...

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...

Caribou Biosciences Appoints Tim Kelly as Chief Technology

-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be...

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

BERKELEY, Calif., Sept. 27, 2023 -- Caribou Biosciences, Inc. , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the...

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

BERKELEY, Calif., July 13, 2023 -- Caribou Biosciences, Inc. , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten...